A Phase 2 Multiple Dose, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of ABBV-8E12 in Subjects with Early Alzheimer’s Disease

The study is designed to examine the safety and efficacy of a drug that targets the protein tau in the brains of people with Alzheimer’s disease. Research has shown that cognitive decline in patients with Alzheimer’s disease may relate to levels of abnormal tau protein in the brain.

More information is attached.